Skip to main content

Market Overview

Elbit Imaging Announces Novartis to Invest $5M in Gamida for ~2.5% Stake


Elbit Imaging Ltd. (NASDAQ: EMITF) announced today, further to its announcement on June 3, 2015, that Gamida Cell Ltd. ("Gamida")  an indirect Associate of the Company, has entered into agreement with Novartis Pharma AG (NYSE: NVS), which consists of the following material agreements:

At the closing of the Agreement, Novartis will invest in Gamida an immediate amount of $5 million (the "Investment Amount"), in return for approximately 2.5% in Gamida on a fully diluted basis. Novartis will then hold approximately 18% in Gamida on a fully diluted basis.

In addition, in the event that by the end of 2017 Gamida shall raise the minimum remaining funding required to cover the Phase III study of NiCord, by way of an equity investment, Novartis will invest in Gamida, subject to certain conditions set in the Agreement, an additional amount of up to US$ 10 million (the "Future Investment").

The closing of the Agreement is conditioned upon certain standard conditions as described in the Agreement.

The Company holds approximately 82.7% of the share capital of Elbit Medical Technologies Ltd. (TASE: EMTC-M) (on a fully diluted basis) which, in turn, will hold, after

See full press release


Related Articles (EMITF + NVS)

View Comments and Join the Discussion!

Posted-In: M&A News Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at